Wednesday, January 30, 2013

Clinical Oncology News: Ibrutinib

We finally published the phase I study of ibrutinib in NHL/CLL.  The article was written up in the Journal of Clinical Oncology.  This paper will probably be cited quite a few times and is worth the read for the interested reader.

For readers interested in B-Cell Receptor signaling, they might like to read the original fostamatinib study we published in Blood a few years ago.

Hopefully we will get some of the CAL-101 data written up soon.

A lot of this might seem like Greek, but I was asked to write a summary article for "Clinical Oncology News."  Here is a link to that article

Here is a small quote:

"The BCR signaling pathway is central to B-cell survival. In laboratory conditions where B-cell signaling could be genetically eliminated, B cells disappeared.1 Pharmacologic intervention in downstream signaling pathway proteins intuitively followed, and inhibition of the proximal signaling enzyme spleen tyrosine kinase (Syk) by fostamatinib was initially proposed in only 2007.2

Since that time, numerous clinical investigations have validated the importance of inhibition of BCR signaling. After Syk activation, BTK propagates the signal leading to downstream activation of phosphoinositide-3 kinase. These latter two proteins are inhibited by ibrutinib and CAL-101 (subsequently GS-1101, now idelalisib), respectively. Following the initial clinical reports of fostamatinib activity,3 the present paper by Advani et al represents the first published report of the clinical activity of ibrutinib.

In CLL, virtually all patients experience a rapid reduction in lymph node size and disease-related cytokines concurrently with a rapid rise in white blood cells (WBCs) as cells redistribute from their protective niches in nodes and marrow into the circulation. Over time, WBCs fall, nodes remain reduced, and improvement in marrow function is common, even in high-risk refractory disease. Different NHLs have been observed to respond as well. Some cases of diffuse large B-cell lymphomas may respond in dramatic fashion, although prospective identification of these patients is an area of intense interest. Patients with mantle cell lymphoma have enjoyed durable disease control with ibrutinib. Follicular lymphoma appears to respond to both ibrutinib and idelalisib, yet the clinical significance in this more indolent population requires further study.

Investigators and patients alike are excited because these oral drugs provide unique activity while being well tolerated in most cases. These drugs will alter the clinical management landscape of patients with B-cell malignancies in the near future and practicing clinicians will need to be aware of this emerging class of therapies.

References

  1. Kraus M, Alimzhanov M, Rajewski N, et al. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 2004;117:787-800, PMID: 15186779.
  2. Sharman J, Irish J, Coffee G. Targeting syk kinase for the treatment of b-cell lymphoma. J Clin Oncol. 2007;25(18s):Abstract 3600.
  3. Friedberg J, Sharman J, Sweetenham J. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578-2585, PMID: 19965662.


I have a bunch of posts I want to write but haven't had time to write them.  Hopefully something more soon.


Tuesday, January 22, 2013

Patient Power: "What is Hot in CLL"

I had the pleasure of meeting Andrew Schorr at ASH this past December.  Andrew is a CLL patient who has an absolutely fantastic website called patientpower.  I highly encourage you look through his material.

He asked me, "What is hot in CLL?"  There is a lot going on in CLL.  Here is the interview (I will try to directly embed this on my blog once I figure out how)


An Expert's Perspective: Why New CLL Treatments Supersede FCR from Patient Power® on Vimeo.

Saturday, January 12, 2013

What is Tumor Lysis Syndrome (TLS)?

Tumor Lysis Syndrome (TLS) is the term applied to the death of cancer cells at a rate that exceeds the body's abilities to deal with the consequences.  While we normally think of a "tumor" as a solid mass, this syndrome is probably more common in the lymphomas and leukemias then it is in cancers of the lung, breast, colon, and prostate.

While we might think that killing cancer cells is a good thing - killing too many at once can be a disaster.  In general this is a sufficiently uncommon problem that most patients do not need to worry about it - but for patients receiving treatment for any lymphoma or leukemia it is reasonable to ask your doctor if it is much of a concern and what to watch for.  I find that most patients are pretty unfamiliar with TLS so I though a brief description might be useful for patients who want to understand more.

In human physiology, cells have an extremely important boundary called the "plasma membrane."  It essentially is the zip-lock bag that keeps the insides in and the outsides out.  It is pretty remarkable because the insides of cells are a lot different in composition than the environment outside of the cells.  Cells spend a lot of energy keeping things that way.

If you consider something simple like potassium - there is a lot of it inside of cells and very little outside of cells.  Sodium is the exact opposite - lots on the outside and not much inside.  This separation of ions is important because it serves as the basis of a lot of electrical impulses in a wide variety of cells.

Under appropriate stimuli, you get a sudden reversal of these ion distributions.  Sodium flows in through specific protein channels and potassium can flow out just as quickly (so that we don't spark).  This creates an electrical current that can serve a ton of important physiologic needs.  In nerve tissues, it is what helps send nerve impulses all the way from your toe to your brain.  In cardiac muscle, it is what helps coordinate your heart beat.  In B-cells it helps the b-cell identify that the b cell receptor just found the virus it was supposed to fight off.

Just like all aspects of human physiology, things can go wrong.  Push yourself too hard in a sporting event and you overwhelm your skeletal muscles ability to keep things in balance - you get a cramp.  In cancer medicine, we occasionally encounter "tumor lysis syndrome" where we kill off a bunch of cancer cells all at once - and the insides of the cells ends up outside the cells causing a variety of problems.  Do this slowly enough and the kidneys and the liver clean up the mess.  Do it too quickly and those organs can't keep up.

Since we already talked about sodium and potassium we might as well start there.  When too many cancer cells die at once (and the inside / outside barrier breaks down), you can sometimes see sudden dangerous elevations of potassium.  While potassium is normally a good thing too much potassium is very dangerous.  As I mentioned above, potassium balance helps your heart beat right.  While the body is pretty good at adjusting to slow changes, if you suddenly raise your potassium it causes the electrical impulses of the heart to become ineffective and in extreme cases can cause it to stop.  Fortunately we can often bring it back down by giving lots of IV fluids, diuretics, insulin, sugar, and even something that helps you poop it out.  Administering calcium can help reset the balance as well.  Sometimes people even need temporary dialysis to get rid of the extra potassium.

Potassium isn't the only problem though.  All that cellular DNA has to go somewhere.  It gets broken down into a compound known as uric acid.  Folks with gout probably know a little about uric acid because it can sometimes form crystals in joints like the big toe or the knee which can be extremely painful.  In tumor lysis syndrome, sometimes those crystals form in the kidney and can cause significant organ dysfunction.

Once again, there are lots of things we can do to prevent this like IV fluids (to flush the through), change the pH of the urine so that it is harder for crystals to form, administer a medication (allopurinol) that prevents the formation of uric acid, or even a super expensive medication known as rasburicase which can break it down into smaller molecules super fast.

Phosphorus can also cause problems as it oozes out of dying cells.  Phosphorus likes to bind onto calcium and make calcium-phosphate.  In bad tumor lysis syndrome that can cause your calcium to start to fall (another problem with muscle tissue), or it can even form crystals in blood vessels and block blood flow to the skin.  That would typically be in a pretty extreme case of tumor lysis.

So while killing cancer cells is a good thing - you don't want to kill them all too fast.

Tumor lysis syndrome is most common in the really fast growing blood cancers like acute leukemia (not chronic) or the intermediate / high grade lymphomas like DLBCL or Burkitts.  See my post on the difference between these.  Sometimes these cancers grow so fast that you see an "intrinsic" tumor lysis syndrome even without any sort of treatment.  The cells are proliferating so quickly that the ones dying around the edges can cause all of the problems above.

It is pretty uncommon in the slow growing lymphomas and infrequent in CLL though more of a problem with some of the very effective treatments we have now (including FCR and some research drugs).

As in most things medical we need to be able to quantify TLS.  Therefore there are two categories of TLS - laboratory TLS and clinical TLS.  In the former, there may just be some mild asymptomatic laboratory changes.  In clinical TLS you have laboratory TLS and either kidney dysfunction, heart arrhythmias, or seizures.  Clinical TLS is graded on a scale from 0-5 with 0 being mild kidney abnormality and 5 being fatal.

In 8 years of practicing oncology I cannot recall a patient who either had a seizure or died from TLS (read: uncommon), though I have certainly seen bad electrolyte changes, renal function shutting down (though it typically comes back), and cardiac rhythm abnormalities.  That said, I am aware of a number of my colleagues who have taken care of a case that got that bad.

Anyhow - I am struggling with how to end this post.  I do not want to alarm patients unnecessarily, but I was thinking about tumor lysis syndrome and figured a good number of patients may not be aware of what it is.  This is meant more for education than any specific warning.  Hopefully I have not added to the anxieties of having one of these diseases.

Once again - thanks for reading!